Charleston Laboratories, Inc.

BOSTON, Aug. 2, 2022 /PRNewswire/ -- Ariadne Labs, in collaboration with CaroNova, a health innovation incubator for the Carolinas, recently concluded the first phase of the Home Hospital Early Adopters Accelerator to support health care systems to further develop their own home hospital programs. Through this 40-week program, a total of 91 representatives from 18 health systems in the U.S. and South Africa joined in an agile fused network to rapidly design 20 tools to support successful home hospital programs. In November 2020, the Centers for Medicaid and Medicare Services expanded their Hospital Without Walls initiative to include the Acute Hospital Care at Home Waiver. Since then, many hospitals and health systems across the United States have been working to expand their services to treat acutely ill patients in the home. Home hospital programs have been shown to have numerous benefits, including lower costs and readmission rates, yet successfully developing and launching these programs can be challenging. With pro bono support from Scrum Inc., Accelerator participants used the Scrum agile project management framework to collaborate, design, and develop the tools needed to address the common needs and challenges early adopters face as they implement new home hospital programs. Tools developed include criteria for identifying which patients are eligible for home hospital services, workflows for admissions, IV medications, and escalation, and solutions for software, food services, and oxygen use, among others. The health systems involved in the accelerator will now apply these tools to their own efforts to create or expand their home hospital program. The Accelerator was led by David Levine, MD, MPH, a practicing general internist and investigator at Brigham and Women's Hospital and Harvard Medical School, associate faculty at Ariadne Labs, and an internationally recognized leader in home hospital. He is the head of Ariadne's Home Hospital initiative, which seeks to generate and disseminate the evidence to deliver advanced care at home so that patients can stay at home no matter their health concerns. "Studies have shown that home hospital care translates to less readmission, better experience, and improved physical activity for patients, not to mention capacity creation for strained hospitals," said Levine. "With the tools that the Accelerator has developed over the last 40 weeks, I am excited to see these agile institutions deliver acute care at home with precision." "Through participation in the Accelerator, hospitals and health systems across the Carolinas are now better equipped to launch their home hospital programs," said Jai Kumar, MPH, Senior Director of Program Design at CaroNova. "I look forward to seeing the incredible progress made in these 40 weeks translated into improved care for patients across our region." The hospitals and health systems participating in the Accelerator include: CaroMont Health Cape Fear Valley Carteret Health Care Discovery Health H. Lee Moffitt Cancer Center & Research Institute Healing Hands Healthcare McLeod Health Medical University of South Carolina Health Charleston Novant Health Roper Saint Francis Healthcare Scotland Healthcare Sentara Healthcare The MetroHealth System UNC Health Vanderbilt University Medical Center Tidelands Waccamaw Community Hospital WakeMed Health and Hospitals Wentworth-Douglass Hospital About Ariadne Labs: Ariadne Labs is a joint center for health systems innovation at Brigham and Women's Hospital and the Harvard T.H. Chan School of Public Health. With a mission to save lives and reduce suffering, our vision is that health systems equitably deliver the best possible care for every patient, everywhere, every time. We use human centered design, health systems implementation science, public health expertise, and frontline clinical care experience to design, test and spread scalable systems-level solutions to some of health care's biggest problems. From developing checklists and conversation guides to fostering international collaborations and establishing global standards of measurement, our work has been accessed in more than 165 countries, touching hundreds of millions of lives. Media Contact: Brigid Tsai Email: [email protected] About CaroNova: CaroNova is a bi-state team established through a partnership among The Duke Endowment, the North Carolina Healthcare Association, and the South Carolina Hospital Association. CaroNova engages with critical stakeholders to effect positive change in health across North and South Carolina. Acting as a connector of people and ideas for the two states, CaroNova addresses common areas of need by supporting promising new practices and developing business models to scale and sustain what works for systemic change. The name CaroNova translates to creating a new vision (Nova) of health for the Carolinas (Caro). Please visit CaroNova.org to learn more. Media Contact: Jill Armbruster Email: [email protected] SOURCE Ariadne Labs

The migraine market is expected to surge due to the increasing prevalence of the disease along with increasing awareness during the forecast period. Furthermore, the launch of various multiple-stage pipeline products will significantly revolutionize the migraine market dynamics. LAS VEGAS, June 15, 2022 /PRNewswire/ -- DelveInsight's Migraine Market Insights report includes a comprehensive understanding of current treatment practices, Migraine emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan. Key Takeaways from the Migraine Market Report As per DelveInsight analysis, the migraine market size in the 7MM was approximately USD 6.9 billion in 2021. As per the estimates, the total Migraine prevalent cases in the 7MM was approximately 118 million in 2021. Leading Migraine companies such as Lundbeck Seattle BioPharmaceutical, Eli Lilly and Company, Amgen, Novartis, Teva Pharmaceuticals, Allergan, Biohaven Pharmaceuticals, Dr. Reddy's Labs, AbbVie, Impel NeuroPharma, Zosano Pharma, Axsome Therapeutics, Aeon Biopharma Inc., Ionis Pharmaceuticals, Inc., Charleston Laboratories , and others are developing novel migraine drugs which can be available in the migraine market in the upcoming years. The migraine therapies in the pipeline include BHV-3500 (Zavegepant), Atogepant, INP104, Zolmitriptan transdermal, AXS-07, Lu AG09222, ABP-450, IONIS-PKKRx, Oral CL- H1T, LY-3451838, and others. The increased number of migraine cases and the emerging treatment are likely to contribute directly to the migraine market growth during the forecast period. Discover more about therapies set to grab major migraine market share @ Migraine Market Landscape Migraine Overview Migraine is the seventh most debilitating disease in the world (responsible for 2.9% of all years of life lost to disability/YLDs) and the leading cause of impairment among all neurological disorders. Migraine is classed as chronic or episodic based on the type of the attack and its frequency. Episodic migraine is defined as having 0–14 headache days per month, and chronic migraine is defined as having 15 or more headache days per month. Although migraine symptoms usually include severe throbbing recurring pain on one side of the head, one-third of migraine attacks are found to be affected on both sides. Among the most common migraine causes include stress, physical factors, food additives, and others. MRI and CT scans are mainly used for migraine diagnosis. Migraine Epidemiology Segmentation As per DelveInsight, there were approx 118 million Migraine prevalent cases in the 7MM in 2021. Among the EU5 countries, Germany had the highest migraine prevalence in 2021. The Migraine market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Prevalence of Migraine Prevalent Cases of Migraine by severity Gender-specific Prevalence of Migraine Diagnosed Cases of Episodic and Chronic Migraine Download the report to understand which factors are driving migraine epidemiology trends @ Migraine Epidemiological Insights Migraine Treatment Market The key revenue-generating components of the acute migraine treatment market can be roughly characterized as triptans, NSAIDs, analgesics/opioids, and DHE (dihydroergotamine) or ergot alkaloids. Triptans continue to dominate the entire acute therapy landscape in terms of revenue generation. Some of the major migraine drugs (generics/branded) belonging to this class are eletriptan, almotriptan, sumatriptan, rizatriptan, zolmitriptan, and others. Moreover, preventive/prophylactic treatment is used to minimize the frequency, intensity, and duration of migraine attacks. Preventive migraine medicines approved by the FDA include propranolol, timolol, divalproex sodium, OnabotulinumtoxinA (botox), and topiramate; other drugs have demonstrated effectiveness but need FDA clearance. Apart from these, the other FDA approved drugs used for migraine treatment are Vyepti (Eptinezumab) (Lundbeck Seattle BioPharmaceutical), Emgality (Galcanezumab-gnlm) (Eli Lilly and Company), Aimovig (Amgen/Novartis), Ajovy (Teva Pharmaceuticals), Ubrelvy (Allergan), Rimegepant (Nurtec ODT) (Biohaven Pharmaceuticals), and others. To know more about migraine treatment, visit @ Migraine Medications Migraine Pipeline Therapies and Key Companies BHV-3500 (Zavegepant): Biohaven Pharmaceuticals Atogepant: AbbVie INP104: Impel NeuroPharma Zolmitriptan transdermal: Zosano Pharma AXS-07: Axsome Therapeutics Lu AG09222: Lundbeck ABP-450: Aeon Biopharma IONIS-PKKRx: Ionis Pharmaceuticals Oral CL- H1T: Charleston Laboratories LY-3451838: Eli Lilly and Company Learn more about the migraine medicine in clinical trials @ Migraine Treatment Migraine Market Dynamics The migraine treatment market looks promising as the market is emerging with newer treatments that have recently been approved by the FDA and are anticipated for approval in the coming years. A large number of clinical phase trials are being done to examine and evaluate promising investigational therapies and their much-awaited launch owing to a robust therapeutic treatment market and bolstering the treatment response as a whole. Moreover, the increasing disease prevalence and awareness will fuel the migraine market during the forecast period. However, some factors are hindering the growth of the migraine market. Despite the availability of standard treatment guidelines across regions and the well-entrenched presence of an array of available, mostly inexpensive options, current abortive and prophylactics, lack of biomarkers, and lack of therapies for pediatric patients exist as a high unmet need which is contrary to the popular perception. The therapies addressed in recent are not effective in all patients, have contraindications related to cardiovascular conditions in some patients, and are nonspecific or poorly tolerated in others. In addition, the undiagnosed, unreported cases and the unawareness about the disease remain the primary aspects that strive for the migraine market growth. Scope of the Migraine Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Migraine Companies: Lundbeck Seattle BioPharmaceutical, Eli Lilly and Company, Amgen, Novartis, Teva Pharmaceuticals, Allergan, Biohaven Pharmaceuticals, Dr. Reddy's Labs, AbbVie, Impel NeuroPharma, Zosano Pharma, Axsome Therapeutics, Aeon Biopharma Inc., Ionis Pharmaceuticals, Inc., Charleston Laboratories, and others Key Migraine Therapies: BHV-3500 (Zavegepant), Atogepant, INP104, Zolmitriptan transdermal, AXS-07, Lu AG09222, ABP-450, IONIS-PKKRx, Oral CL- H1T, LY-3451838, and others Therapeutic Assessment: Migraine current marketed and emerging therapies Migraine Market Dynamics: Migraine market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, Migraine Market Access and Reimbursement Discover more about migraine drugs in development @ Migraine Clinical Trials Table of Contents Get in touch with our Business executive @ Healthcare Due Diligence Services Related Reports Migraine Epidemiology Migraine Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Migraine epidemiology in the 7MM. Migraine Pipeline Migraine Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Migraine companies including Allergan, Biohaven Pharmaceuticals, Dr. Reddy's Labs, AbbVie, among others. Cluster Headache Market Cluster Headache Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Cluster Headache companies including Eli Lilly and Company, Teva Pharmaceuticals, Novartis, among others. Cluster Headache Epidemiology Cluster Headache Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Cluster Headache epidemiology in the 7MM. Cluster Headache Pipeline Cluster Headache Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Cluster Headache companies including Eli Lilly and Company, Teva Pharmaceuticals, Novartis, among others. Other Trending Reports Glomerulonephritis Market | Lymphedema Market | Audiology Devices Market | Campylobacter Infections Market | Varicose Veins Market | Nasolabial Fold Market | Reactive Airway Disease Market | Scleritis Market | Contrast-Induced Nephropathy Market | Mucinous cystic neoplasms Market | Metastatic Uveal Melanoma Market | ICOS-Next Generation Immunotherapy Market | Herpes Simplex Market | Hepatitis C Market | Guillain-Barre Syndrome Market | Graft Versus Host Disease Market | Goitre Market Related Healthcare Blogs Neuromodulation Devices in Migraine Migraine Treatment Market Migraine Market Outlook About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP